![](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2024/07/shutterstock_1192950880-e1720021656354.jpg)
Beacon secures $170m to advance ophthalmic gene therapies
Beacon Therapeutics has raised $170m in a Series B funding round to accelerate the development of its lead asset AGTC-501, for X-linked retinitis pigmentosa (XLRP). The financing round was led by life sciences venture capital firm Forbion, alongside …